HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hollands, J. M. Articles by Young, S. Search for Related Content PubMed PubMed Citation Articles by Hollands, J. M. Articles by Young, S.

JAMES M. HOLLANDS, PHARM.D., is Clinical Pharmacist, Cardiac Intensive Care Unit, Barnes-Jewish Hospital, St. Louis, MO. EDWARD F. FOOTE, PHARM.D., is Associate Professor, Department of Pharmacy Practice Nesbitt College of Pharmacy and Nursing, Wilkes University, Wilkes-Barre, PA. ALFONSO RODRIGUEZ, M.D., JOHN ROTHSCHILD, M.D., and STEVEN YOUNG, D.O., are Nephrologists, Renal Consultants of Wyoming Valley, Wilkes-Barre, PA.

Address correspondence to Dr. Foote at the Department of Pharmacy Practice, Nesbitt College of Pharmacy and Nursing, Wilkes University, 84 West South Street, Wilkes-Barre, PA 18766 (edward.foote{at}wilkes.edu).

Purpose. The safety of high-dose iron sucrose infusion in hospitalized patients with chronic kidney disease was studied. Methods. A retrospective analysis was conducted at a 478-bed community hospital. A medical informatics search was performed to identify all hospitalized patients who were prescribed i.v. iron sucrose to deliver elemental iron 300 mg every other day for three doses between January and December 2002. Patients were eligible for inclusion in the analysis if they had chronic kidney disease, had an estimated creatinine clearance of <60 mL/min, and were prescribed the above regimen. Information on iron administration, vital signs, hematologic values, and iron indexes was gathered from patients’ medical records. Medical record review was also used to identify possible adverse events. Results. A total of 73 patients met eligibility criteria and received a total of 167 doses of iron sucrose. Twenty adverse events were judged as possibly related to iron sucrose administration and included nausea (n = 8 events), reduced blood pressure (n = 4), vomiting (n = 2), dysgeusia (n = 2), constipation (n = 2), fatigue (n = 1), and anxiety (n = 1). The majority of these adverse events were low in severity, as determined by an objective scale. No severe adverse events occurred. There was no association between infusion rate and the occurrence of potential adverse events (p = 0.44). Conclusion. Every-other-day i.v. infusion of iron sucrose, to deliver elemental iron 300 mg/dose, was associated with adverse events that were relatively uncommon, minor in severity, and unlikely to require medical intervention. Index terms: Anemia; Drug administration rate; Iron preparations; Iron sucrose; Kidney diseases; Toxicity

 

This article has been cited by other articles:

				M. MacKay, W. Rusho, D. Jackson, G. McMillin, and B. Winther Physical and Chemical Stability of Iron Sucrose in Parenteral Nutrition Nutr Clin Pract, December 1, 2009; 24(6): 733 - 737. [Abstract] [Full Text] [PDF]

				N. Brown, D. H. Henry, and P. A. Ford Manageable Side Effects of Intravenous Iron in a Community Practice Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 4687 - 4687. [Abstract]

				G. C. Wall and R. A. Pauly Evaluation of total-dose iron sucrose infusions in patients with iron deficiency anemia Am. J. Health Syst. Pharm., January 15, 2008; 65(2): 150 - 153. [Abstract] [Full Text] [PDF]

				N. B. O'Mara Anemia in Patients With Chronic Kidney Disease Diabetes Spectr, January 1, 2008; 21(1): 12 - 19. [Abstract] [Full Text] [PDF]